Auriga Reiterates a 'Buy' on Omnicell (OMCL); In-line Earnings and MTS Acquisition
Tweet
Share
E-mailGet Alerts OMCL Hot Sheet
Price: $37.30 -0.9%
Rating Summary:
12 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Auriga reiterates a 'Buy' on Omnicell (NASDAQ: OMCL) price target of $19.00.
Analyst, Gene Mannheimer, said, "We are reiterating our rating on OMCL on the heels of in-line quarter and guide. Concurrent with earnings, OMCL announced the acquisition of MTS Medication Technologies for $156 million in cash. The acquisition is consistent with our published view that OMCL would look to alternative markets in order to grow, as traditional cabinet sales in acute care hospitals are well penetrated. MTS, which leads the market in medication adherence packaging, plays well into OMCL's theme of medication safety and extends the chain beyond the four walls of the hospital to the continuum of care. We expect the transaction to close in June or July, and at this time our estimates exclude the contribution from MTS, though management expects $0.15-$0.17 non-GAAP EPS accretion in 2013."
For an analyst ratings summary and ratings history on Omnicell click here. For more ratings news on Omnicell click here.
Shares of Omnicell closed at $14.27 yesterday.
Analyst, Gene Mannheimer, said, "We are reiterating our rating on OMCL on the heels of in-line quarter and guide. Concurrent with earnings, OMCL announced the acquisition of MTS Medication Technologies for $156 million in cash. The acquisition is consistent with our published view that OMCL would look to alternative markets in order to grow, as traditional cabinet sales in acute care hospitals are well penetrated. MTS, which leads the market in medication adherence packaging, plays well into OMCL's theme of medication safety and extends the chain beyond the four walls of the hospital to the continuum of care. We expect the transaction to close in June or July, and at this time our estimates exclude the contribution from MTS, though management expects $0.15-$0.17 non-GAAP EPS accretion in 2013."
For an analyst ratings summary and ratings history on Omnicell click here. For more ratings news on Omnicell click here.
Shares of Omnicell closed at $14.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Diana Shipping withdraws bid to acquire Genco Shipping
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Mergers and AcquisitionsRelated Entities
Auriga, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
